Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/16/2025

Management of Antithrombotic Therapy in Patients with Ischemic Stroke

Introduction to Antithrombotic Therapy Management

  • The American Heart Association recommends that the suspension of antiplatelet agents and anticoagulants in patients with ischemic stroke should only be done in specific situations such as intracranial hemorrhage, preparation for high-risk surgical procedures, or when changing to another antithrombotic therapy based on the etiology of the stroke 1
  • The American College of Cardiology suggests that antiplatelet therapy should not be routinely suspended in patients with non-cardioembolic ischemic stroke, as these medications are fundamental for secondary prevention 2

Hemorrhage Management

  • In patients who develop intracranial hemorrhage (ICH), subarachnoid hemorrhage (SAH), or subdural hematoma (SDH), all antiplatelet agents should be suspended during the acute period for at least 1-2 weeks after the hemorrhage, with a strength of evidence level of high 1
  • Antiplatelet therapy can be restarted after 3-4 weeks with rigorous monitoring, based on moderate evidence 1
  • In case of intracranial hemorrhage, all anticoagulants should be suspended immediately and the anticoagulant effect should be reversed with appropriate agents (vitamin K, fresh frozen plasma), with a high level of evidence 1

Surgical Procedures

  • Antiplatelet agents should be temporarily suspended for procedures with a high risk of bleeding, with the time of suspension varying according to the antiplatelet agent: aspirin 5-7 days before, clopidogrel 5-7 days before, and ticagrelor 5 days before, based on moderate evidence
  • Anticoagulants should also be temporarily suspended according to the type of anticoagulant: warfarin 5 days before, and direct oral anticoagulants (DOACs) 2-3 days before (longer in case of renal insufficiency), with a high level of evidence 3

Change to Another Antithrombotic Regimen

  • When a cardioembolic cause (such as atrial fibrillation) is identified that requires anticoagulation, antiplatelet therapy should be suspended unless there is a specific indication for combined therapy, with a high level of evidence 2
  • The American Heart Association recommends that in patients with mechanical heart valves, anticoagulation with warfarin should be maintained indefinitely with a target INR of 3.0 (range 2.5-3.5), based on high evidence 2

Specific Situations

  • In patients with atrial fibrillation, direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists, with a high level of evidence 4
  • In patients with left ventricular thrombus after acute myocardial infarction, oral anticoagulation should be maintained for at least 3 months, based on moderate evidence 3
  • The American College of Chest Physicians suggests that in patients with non-valvular atrial fibrillation, DOACs are preferred over vitamin K antagonists, with a high level of evidence 4

Evaluation and Risk Assessment

  • The etiology of the ischemic stroke should be evaluated to determine the appropriate antithrombotic therapy: cardioembolic causes require anticoagulation, while non-cardioembolic causes require antiplatelet therapy, with a high level of evidence 2
  • The risk of bleeding should be assessed, and patients with a high risk of bleeding (history of hemorrhage, varices, vascular anomalies, coagulopathy) should be considered for temporary suspension or dose adjustment of antithrombotic therapy, with a moderate level of evidence
  • In case of intracranial hemorrhage, all antithrombotic agents should be suspended immediately, and the anticoagulant effect should be reversed if necessary, with a high level of evidence 1